Callan JMB Awarded Second 5-Year Contract by the Oregon Health Authority for Emergency Preparedness and Response after Successful Operations for COVID-19 and MPOX Pandemics
11. Februar 2025 09:00 ET
|
Callan JMB Inc.
During COVID, over 800,000 vaccines in Oregon were received, repackaged, and distributed covering over 75,000 miles SPRING BRANCH, Texas, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Callan JMB INC. (NASDAQ:...
Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19
27. Januar 2025 06:30 ET
|
Ocugen
OCU500 will be administered via inhalation and as a nasal sprayCOVID-19 remains a substantial public health threat in the U.S. and around the worldPhase 1 clinical trial is anticipated to start in 2Q...
AIM ImmunoTech Announces Publication of Final Clinical Study Results for AMP-518 Clinical Trial on Ampligen as a Therapeutic for Post-COVID Conditions
23. Januar 2025 08:50 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., Jan. 23, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the final Clinical Study Results for the “Study to Evaluate the...
AIM ImmunoTech Highlights New Article Finding Links Between COVID-19 and ME/CFS
22. Januar 2025 08:30 ET
|
AIM ImmunoTech Inc.
Recently published article on study findings underscores links between study participants infected with SARS-CoV-2 and the incidence of ME/CFS The early-onset broad-spectrum antiviral effect of...
Most Americans Support Pandemic Policies but Have Concerns About Implementation
14. Januar 2025 09:53 ET
|
de Beaumont Foundation
Bethesda, Maryland, Jan. 14, 2025 (GLOBE NEWSWIRE) -- As the U.S. faces continuing infectious disease outbreaks, a new study shows that a majority of Americans are likely to support mitigation...
BioNTech gibt auf der 43. J.P. Morgan Healthcare-Konferenz Updates zur Geschäfts- und Pipeline-Entwicklung
14. Januar 2025 06:45 ET
|
BioNTech SE
BioNTech fokussiert sich in der Umsetzung der Onkologie-Strategie auf tumorübergreifende (Pan-Tumor-) Therapieansätze basierend auf Kombinationen mit BNT327/PM8002 sowie den...
BioNTech Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference
14. Januar 2025 06:45 ET
|
BioNTech SE
Executing in oncology with investigational BNT327/PM8002 combinations and mRNA cancer immunotherapy candidates as pan-tumor treatment approaches BioNTech aims to develop BNT327/PM8002 as a...
AIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and Methods Patent Covering Ampligen for Use in the Post-COVID Condition of Fatigue
12. Dezember 2024 09:00 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., Dec. 12, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Netherlands Patent Office (Octrooicentrum Nederland) has...
COVID Non-pharmaceutical Interventions Were Harmful Authoritarian Overreach, according to Journal of American Physicians and Surgeons
10. Dezember 2024 10:02 ET
|
Association of American Physicians and Surgeons
Pandemic control measures for COVID likely did more damage than the disease itself. They were imposed without sound evidence, ignoring social consequences.
tiakis Biotech AG Reports Clinical Phase Ib/II Trial Results of Tiprelestat for the Treatment of Hospitalized COVID-19 Patients
09. Dezember 2024 04:00 ET
|
AKAMPION
- Tiprelestat was safe and well tolerated, with initial signs of clinical efficacy Kiel, Germany, December 9, 2024 – tiakis Biotech AG, a clinical-stage biopharmaceutical company developing...